Galaxy银河|澳门官网·登录入口

至今,GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次,处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果,再次证明GenScript 有能力帮助业内科学家Make research easy.

Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells

Histol Histopathol. 2021-02; 
Ya-Kun Liu, Ya-Jing Jia, Shi-Hao Liu, Hong-Jie Shi, Jing Ma
Products/Services Used Details Operation
Recombinant Proteins … Dallas, TX, USA) in siRNA transfection medium (Cat. #: sc-36868, Santa Cruz Biotechnology, Inc., 128 Dallas, TX, USA) … Primers were 136 designed with Primer 5.0 software (Table 1) and synthesized by GenScript Biotech Corporation 137 (Nanjing, China) … Get A Quote

摘要

objective: To investigate the effect of the downregulation of FXYD domain-containing ion transport regulator 5 (FXYD5) on the cisplatin resistance (CisR) of epithelial ovarian cancer (EOC) cells. methods: A2780-CisR and SKOV3-CisR cells were obtained through repeated administrations of different cisplatin concentrations, and the half-maximal inhibition concentration (IC50) was calculated by MTT assays. After transfection with FXYD5 siRNA-1 and FXYD5 siRNA-2, the IC50 values of the A2780-CisR and SKOV3-CisR cells were also detected by the MTT method. Cell proliferation, migration, invasion and apoptosis were evaluated through 5-ethynyl-2'-deoxyuridine (EdU) DNA synthesis, wound healing, Transwell invasion and An... More

关键词

XML 地图